19
May
2022
PureTech Health plc
PDMR Notifications
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases,
announces that
awards of restricted share units ("RSUs") granted by PureTech on 20 December 2019 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested at 95.8% on 3 February 2022 following satisfaction of performance conditions
measured over the three year period to 31 December 2021. In addition, certain RSUs granted to George Farmer, PureTech's Chief Financial Officer, pursuant to its PSP vested in full on 1 January 2022 in accordance with a time-based vesting schedule.
Each PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 18 May 2022.
The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 175 pence, being the average closing price of the Company's shares over the three trading day period immediately preceding the settlement, and the exchange rate used to calculate the cash payment and amount of share settlement was £1:$1.2359.
The Company's total issued ordinary share capital is
288,611,159
shares after the share issuance to the PDMRs.
PDMR Notification
The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a)
|
Name
|
Daphne Zohar
Bharatt Chowrira
Eric Elenko
Joseph Bolen
George Farmer
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Daphne Zohar - Chief Executive Officer
Bharatt Chowrira - President and Chief Business, Legal and Operating Officer
Eric Elenko - Chief Innovation and Strategy Officer
Joseph Bolen - Chief Scientific Officer
George Farmer - Chief Financial Officer
|
|
b)
|
Initial notification/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
PureTech Health plc
|
|
b)
|
LEI
|
213800LVPDNO2Z9T9I39
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
|
|
Ordinary Shares of PureTech Health plc
ISIN GB00BY2Z0H74
|
|
|
|
b)
|
Nature of the transaction
|
Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes.
|
|
c)
|
Price(s) and volume(s)
|
|
Recipient
|
Price
|
Amount
|
|
Daphne Zohar
|
0.01 GBP
|
366,882 ordinary shares
|
|
Bharatt Chowrira
|
0.01 GBP
|
69,600 ordinary shares
|
|
Eric Elenko
|
0.01 GBP
|
127,476 ordinary shares
|
|
Joseph Bolen
|
0.01 GBP
|
127,476 ordinary shares
|
|
George Farmer
|
0.01 GBP
|
18,282 ordinary shares
|
|
|
d)
|
Aggregated information
|
|
Price
|
Aggregate Volume
|
|
0.01 GBP
|
709,717 ordinary shares
|
|
|
e)
|
Date of the transaction
|
18 May 2022
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders.
This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Contact:
PureTech
Investor Relations
[email protected]